Igurator 25 Tablet contains Iguratimod 25 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of rheumatoid arthritis (RA). Iguratimod exerts its therapeutic effects by inhibiting the production of inflammatory cytokines and suppressing the activation of nuclear factor-kappa B (NF-κB), thereby reducing synovial inflammation and joint destruction. This medication is utilized to improve clinical symptoms, physical function, and inhibit the progression of structural damage in patients with active RA. Igurator 25 is typically administered orally once or twice daily, with or without food, as prescribed by a healthcare professional. It may be used as monotherapy or in combination with other antirheumatic agents such as methotrexate. Common adverse effects include gastrointestinal disturbances, elevated liver enzymes, and mild hematological abnormalities; therefore, regular monitoring of liver function tests and blood counts is recommended during treatment. Igurator 25 should be used cautiously in patients with hepatic or renal impairment and is contraindicated in individuals with known hypersensitivity to Iguratimod or its excipients. Pregnant or breastfeeding women should avoid this medication unless clearly indicated by a physician. Patients are advised to adhere strictly to prescribed dosages and consult their healthcare provider if adverse reactions or signs of infection occur.